PMID- 37539240
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230805
IS  - 2405-8440 (Print)
IS  - 2405-8440 (Electronic)
IS  - 2405-8440 (Linking)
VI  - 9
IP  - 7
DP  - 2023 Jul
TI  - Myeloprotection with activated carbon in doxorubicin-treated rats.
PG  - e18414
LID - 10.1016/j.heliyon.2023.e18414 [doi]
LID - e18414
AB  - Chemotherapy can often cause a variety of side effects including bone marrow (BM) 
      suppression, termed as myelosuppression. Accordingly, facile and effective 
      management of chemotherapy-induced myelosuppression is currently a pivotal task 
      for experimental pathologists and oncologists. Here, we chose to use activated 
      carbon (AC) with an extensive surface area for studying its possible protective 
      effectiveness with respect to BM in doxorubicin (DOX)-treated rats. Spherical AC 
      with an extended surface area up to 4490 m(2)/g was prepared for per os (p/o) 
      delivery, whereas for intraperitoneal (i/p) delivery we used the powdered form of 
      AC that was derived from the aforementioned spherical AC. During the monthly 
      treatment of animals with AC and DOX these two components were delivered 
      alternately (not in the same day). After treatment, BM cells were isolated from 
      femurs of sacrificed animals, stained with acridine orange (AO) and analyzed by 
      flow cytometry. Regardless of the route of AC delivery (p/o or i/p), apparent 
      myeloprotection with a possible regenerative effect was observed in animals that 
      received DOX, as evidenced by recovery of the populations of total nucleated 
      cells (TNC) and polychromatic (immature) erythrocytes accompanied by a 
      considerable reduction of the number of apoptotic/dead cells among TNC (</=2.0%). 
      Moreover, as a result of AC administrations, there was a significant increase of 
      AO green and far-red fluorescence intensities in the population of TNC, which is 
      suggestive of the ongoing quantitative and conformational changes in DNA and RNA 
      associated with cell recovery and proliferation. Thus, AC preparations under the 
      present experimental conditions can effectively tackle DOX-induced 
      myelosuppression via mechanisms not necessarily associated with adsorptive 
      detoxification.
CI  - (c) 2023 The Authors.
FAU - Gerashchenko, Bogdan I
AU  - Gerashchenko BI
AD  - R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology 
      (IEPOR), National Academy of Sciences of Ukraine, Vasylkivska Str. 45, Kyiv, 
      03022, Ukraine.
FAU - Sarnatskaya, Veronika V
AU  - Sarnatskaya VV
AD  - R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology 
      (IEPOR), National Academy of Sciences of Ukraine, Vasylkivska Str. 45, Kyiv, 
      03022, Ukraine.
FAU - Bardakhivska, Kvitoslava I
AU  - Bardakhivska KI
AD  - R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology 
      (IEPOR), National Academy of Sciences of Ukraine, Vasylkivska Str. 45, Kyiv, 
      03022, Ukraine.
FAU - Sydorenko, Oleksii S
AU  - Sydorenko OS
AD  - R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology 
      (IEPOR), National Academy of Sciences of Ukraine, Vasylkivska Str. 45, Kyiv, 
      03022, Ukraine.
FAU - Kolesnik, Denis L
AU  - Kolesnik DL
AD  - R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology 
      (IEPOR), National Academy of Sciences of Ukraine, Vasylkivska Str. 45, Kyiv, 
      03022, Ukraine.
FAU - Klymchuk, Dmytro O
AU  - Klymchuk DO
AD  - M.G. Kholodny Institute of Botany, National Academy of Sciences of Ukraine, 
      Tereshchenkivska Str. 2, Kyiv, 01601, Ukraine.
LA  - eng
PT  - Journal Article
DEP - 20230718
PL  - England
TA  - Heliyon
JT  - Heliyon
JID - 101672560
PMC - PMC10393748
OTO - NOTNLM
OT  - Acridine orange
OT  - Activated carbon
OT  - Bone marrow
OT  - Doxorubicin
OT  - Flow cytometry
OT  - Fluorescence intensity
OT  - Hematopoiesis
OT  - Myeloprotection
OT  - Polychromatic erythrocytes
OT  - Total nucleated cells
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2023/08/04 06:43
MHDA- 2023/08/04 06:44
PMCR- 2023/07/18
CRDT- 2023/08/04 04:12
PHST- 2023/04/12 00:00 [received]
PHST- 2023/07/15 00:00 [revised]
PHST- 2023/07/17 00:00 [accepted]
PHST- 2023/08/04 06:44 [medline]
PHST- 2023/08/04 06:43 [pubmed]
PHST- 2023/08/04 04:12 [entrez]
PHST- 2023/07/18 00:00 [pmc-release]
AID - S2405-8440(23)05622-0 [pii]
AID - e18414 [pii]
AID - 10.1016/j.heliyon.2023.e18414 [doi]
PST - epublish
SO  - Heliyon. 2023 Jul 18;9(7):e18414. doi: 10.1016/j.heliyon.2023.e18414. eCollection 
      2023 Jul.